The Research of Medical Science Review
ISSN: 3007-1208 & 3007-1216 Volume 3, Issue 7, 2025

INSIGHT IN DEVELOPMENT OF NEW VACCINES FOR EMERGING INFECTIOUS DISEASES AND THE IMPACT OF VACCINES ON PUBLIC HEALTH

Furkhanda Kalsoom[1], Rafia Bibi[*2], Farwa Riaz[3], Hasan Ijaz[4], Rahmeen Ajaz[5], Robiana Modjo[6], Muhammad Farhan Liaqat[7], Obaid Muhammad Abdullah[8]

[1]*Department of Medical Laboratory Technology, Riphah International University Faisalabad, Punjab, Pakistan*
[*2]*Faculty of Veterinary and Animal Sciences (FV&AS), PMAS Arid Agriculture University, Rawalpindi, Punjab, Pakistan*
[3]*Department of Social Science, University of Agriculture, Faisalabad, Punjab, Pakistan*
[4]*Department of Allied Health Sciences, Riphah International University, Faisalabad, Punjab, Pakistan*
[5]*Faculty of Public Health, Department of Occupational health and safety, Universitas Indonesia (UI), Jakarta, Indonesia*
[6]*Faculty of Public Health, Department of Occupational health and safety, Universitas Indonesia (UI), Jakarta, Indonesia*
[7]*Department of Biological Sciences, The Superior University, Lahore, Punjab, Pakistan*
[8]*Department of Small Animal Clinical Sciences, University of Veterinary and Animal Sciences, Lahore, Punjab, Pakistan*

[*2]rafiaaqil3@gmail.com

DOI: https://doi.org/10.5281/zenodo.15812065

Keywords
emerging infectious diseases, vaccine development, mRNA vaccines, public health impact, vaccine equity, global immunization, infectious disease preparedness

Article History
Received on 28 May 2025
Accepted on 28 June 2025
Published on 05 July 2025

Corresponding Author: *
Rafia Bibi

Abstract

Emerging infectious diseases remain a substantial danger to world health, as evidenced by recent outbreaks such as COVID-19, Ebola, and Zika, underscoring the imperative for fast and efficient vaccine development. This review examines the current state of vaccine innovation, emphasizing scientific progress, challenges, and the broader public health implications of vaccination initiatives. This review examines the impact of innovative technologies, including mRNA platforms, viral vectors, and protein subunits, on conventional vaccine development by reducing manufacturing time and enhancing adaptability to evolving pathogens. This review examines significant obstacles, such as antigenic variability, regulatory delays, manufacturing constraints, and vaccine reluctance, which persistently impede global immunization initiatives. Case examples of successful vaccinations, such as those for COVID-19 and Ebola, demonstrate how scientific advancement, global cooperation, and public confidence facilitate prompt and effective response. This study also examined the impact of vaccination on reducing the disease burden, enhancing herd immunity, and generating enduring economic benefits for health systems. Equitable vaccine distribution worldwide remains a fundamental concern. Notwithstanding initiatives by organizations such as COVAX, low- and middle-income nations continue to encounter substantial challenges regarding access, logistics, and infrastructure. This study emphasizes the necessity for decentralized manufacturing, efficient regulatory frameworks, and culturally attuned communication strategies to ensure equal access and

acceptability globally. The assessment concludes by outlining future directions and emphasizing the importance of universal vaccines, AI-driven design, regional production centers, and real-time surveillance systems. By combining innovation with equality and readiness, the global community can enhance its ability to address future infectious disease risks. Vaccines are a pivotal instrument in this endeavor, providing the most effective route to durable and robust public health outcomes.

INTRODUCTION

Infectious diseases continue to pose a significant global health threat, underscored by the emergence and re-emergence of pathogens that complicate disease prevention and treatment. Over the last two decades, the emergence of new or previously contained pathogens has led to outbreaks of severe acute respiratory syndrome coronavirus (SARS-CoV), H1N1 influenza, Ebola virus, Zika virus, and, most recently, SARS-CoV-2, the causative agent of coronavirus disease (COVID-19) (Konda et al., 2020). They have demonstrated significant shortcomings in global public health preparedness and the need for accelerated and effective vaccine development measures (Silva-Jr et al., 2022).

Vaccines are considered one of the most effective strategies in public health, as they have remarkably reduced the burden of infectious diseases, averting millions of deaths annually (Czechowicz, 2021). Immunization programs have proven successful, as evidenced by the eradication of smallpox and the near elimination of polio in many parts of the world. Nevertheless, conventional vaccine development is an expensive and lengthy process that typically cannot keep up with the accelerating evolution and spread of new pathogens (Nii-Trebi, 2017). Vaccine design, manufacture, and deployment must be innovated to allow for timely responses during these outbreaks. However, recent progress in the areas of molecular biology, genomics, and biotechnology has made it possible to develop new vaccine platforms (mRNA-based, viral vector, and nanoparticle vaccines) and initiate their clinical evaluation, as they would also be helpful in a pandemic situation (Tao et al., 2022). As we learned in the case of COVID-19, these technologies have the potential for rapid development, scalable production, and higher efficacy. Simultaneously, the pandemic has revealed that vaccination campaigns require other equally valuable notions to be effective: international solidarity, public trust, equity, and robust operational delivery systems (Steinman & Navon-Venezia, 2020).

This review aims to provide a comprehensive and up-to-date overview of the current trends in vaccine development for emerging infectious diseases. This article explores the scientific and logistical challenges, recent technological advancements, and the impact of vaccines on public health at both the individual and population levels (Reperant et al., 2016). The study emphasizes the lessons learned from previous vaccine efforts and their implications for future engagement. This paper also discusses global equity, and the efforts required to guarantee that life-saving vaccines are distributed across populations where needed, irrespective of physical or financial barriers (Boland & O'Riordan, 2019). This review seeks to enhance the discourse on the more effective development and deployment of vaccines against the continually evolving threat of emerging infectious diseases by synthesizing scientific, clinical, and policy insights (Yan et al., 2023).

2. EMERGING INFECTIOUS DISEASES: AN OVERVIEW

Emerging infectious diseases (EIDs) are infections that have recently appeared in a population whose incidence or geographic range is rapidly expanding. As population density, global travel, climate change, and human encroachment on wild animal habitats all trend upward, the suite of these types of infectious diseases poses a unique and evolving target in terms of a moderate public health threat (Liao et al., 2024). EIDs are approximately 60% zoonotic, meaning the transmission of an infectious agent from an animal reservoir to a human host, as seen in cases of Ebola virus, avian influenza, and coronaviruses, such as SARS, MERS, and SARS-CoV-2 (Mostafavi et al., 2021).

Over the 21st century, this has continued to occur with increased frequency, as well as larger-scale EID outbreaks. This trend is driven by a myriad of factors, ranging from land-use change, agricultural intensification, and antimicrobial resistance to environmental degradation and a lack of access to healthcare due to socioeconomic inequalities (Gopinathan et al., 2020). Globalisation and interconnected economies also fuel the spread of pathogens across borders, transforming localised outbreaks into potential global health emergencies. These events underscore the need for effective surveillance systems and rapid response mechanisms that enable the early detection, containment, and mitigation of infectious threats (Ogden et al., 2017).

Some examples of significant EIDs from the past two decades are the 2003 SARS epidemic, the 2009 pandemic of H1N1 influenza, the 2014–2016 Ebola epidemic in West Africa, the 2015–2016 Zika virus outbreak, and the 2019 COVID-19 pandemic (Mostafavi et al., 2021). These events have reminded the world of the susceptibility of public to viral outbreaks and emphasized the need to address the chinks in the present public health structure and adopt faster diagnostic, therapeutic, and vaccine developmental mechanisms. The unpredictable and heterogeneous nature of EIDs also presents significant scientific challenges. Genetic mutations, reassortment, or recombination of pathogens may occur, thereby increasing their ability to evade immune responses and facilitating more efficient transmission. Lentiviral vectors have been established as robust vaccine delivery systems owing to their potent antigenic capacity and tropism for both quiescent and activated B- and T-lymphocytes (Roberts, 2019).

The drivers, trends, and biology of EIDs should be better understood to guide the development of research priorities and public health strategies. Tools such as surveillance data, epidemiological modelling, and cross-sectoral One Health collaboration between human, animal, and environmental health sectors are key to identifying future threats (Zegpi et al., 2017). Vaccine research and innovation should align with these priorities to maximize preparedness for future outbreaks and their health and economic impacts, as EIDs will continue to shape the global health landscape (Maslow, 2019).

3. CHALLENGES IN VACCINE DEVELOPMENT

Vaccine development for emerging infectious diseases faces a myriad of scientific, logistical, and social hurdles as shown in Figure 2. This vagueness is a key scientific challenge, as pathogens defy prediction. During an outbreak of emerging viruses, very little genetic or clinical information is typically available, making it challenging to identify suitable antigens for vaccine candidates. Furthermore, antigenic drift, which occurs due to high mutation rates in particular viruses, such as RNA viruses, can render existing vaccine candidates obsolete (Wolf et al., 2020). Pathogens can also have complex life cycles or exist in various strains or serotypes, necessitating highly specific or multivalent vaccines. However, developing safer and immunogenic vaccines under these constraints generally requires time and several trials (van den Ouweland et al., 2024).

However, even leaving aside scientific issues, logistical and regulatory hurdles to rapid vaccine development have compounded the problem. The traditional journey of developing a vaccine from discovery to market takes 10–15 years; therefore, it is a matter of time. Emergency use authorizations may compress this timeline, but essential steps—such as preclinical studies, staged clinical trials, and regulatory review—cannot be easily shortened without compromising safety or efficacy (Rose et al., 2021). Manufacturing is another major bottleneck in this process. Sophisticated facilities, raw materials, and trained personnel are required to scale production to meet global demand. In low-resource settings, the requirements are often lacking, resulting in unequal vaccine availability during public health crises (Ayenigbara et al., 2021).

Public perception and acceptance are also significant factors in vaccine deployment. Misinformation, distrust of health authorities, and cultural beliefs have contributed to vaccine hesitancy, which can weaken immunization programs (Shoaib et al., 2023). Information warfare, as seen in the reduction of vaccine uptake due to misinformation in specific populations, is a notable example. Public health communication is complicated by a history of mistrust in some areas, resulting from unethical medical practices or political instability. Solving these problems involves more than scientific and industrial solutions; it requires coordinated public education

efforts, community engagement, and transparent policymaking. Without public trust and equitableaccess, even the most advanced vaccines may not have the desired effect on public health (Mahoney et al., 2023).



Figure 2: *This flowchart highlights key stages in the vaccine pipeline and visually flags common barriers to access faced by low- and middle-income countries (LMICs).*

4. ADVANCES IN VACCINE DEVELOPMENT TECHNOLOGIES

The past two decades have witnessed significant advancements in vaccine development technologies, leading to a paradigm shift in vaccine design, production, and delivery methods as shown in Figure 1
. Much of this change has been motivated by emerging infectious diseases, especially during global health emergencies. Consequently, the vaccine landscape has changed by complementing—and in some instances even replacing—traditional inactivated or live-attenuated viruses with next-generation platforms, including mRNA, viral vectors, protein subunits, and DNA-based vaccines. They provide higher flexibility, reduce development timelines, and can be quickly adjusted for ever-mutating pathogens (Sandbrink & Koblentz, 2022).

The development of mRNA vaccine platforms is one of the many important advances made in this field. This is fundamentally different from traditional vaccines, which involve growing pathogens in the laboratory. Instead of using a live virus, they use artificial genetic material to program host cells to produce viral proteins that elicit an immune response. During the COVID-19 pandemic, this approach proved particularly practical, as the Pfizer-BioNTech and Moderna vaccines were developed and marketed in under a year (Sa et al., 2022). In addition, mRNA vaccines are relatively easy to reshape in response to new variants, providing a significant boost in controlling rapidly evolving viruses (Ben Hamouda et al., 2024).

Another innovation is viral vector vaccines. These vaccines use harmless viruses, typically adenoviruses, as delivery vehicles to introduce the genetic material of the target pathogen into human cells. The best examples are the English and Johnson & Johnson COVID-19 vaccines, as well as the Oxford-AstraZeneca and Johnson & Johnson vaccines, respectively (Lundstrom, 2020). Other types of vaccines being explored include protein subunit or nanoparticle-based vaccines, due to their favorable safety profiles and stability. Moreover, advancements in adjuvant formulations enhance both the dose and the immune response, thereby improving the vaccine's efficiency and coverage. The vaccine pipeline has also become more scalable and cost-effective by streamlining production using new bioreactor

technologies, cell-type culture systems, and platform-based manufacturing (Pinschewer, 2017).

Recently, genomic sequencing, artificial intelligence, and bioinformatics have significantly expedited the identification of promising vaccine targets and the optimization of antigens (such as the use of chimeric proteins). Predictive modelling tools can now simulate immune responses, allowing researchers to screen candidates before laboratory testing (Travieso et al., 2022). Collectively, these developments have shifted the goalposts from a reactionary to an anticipatory vaccine research process. However, despite these advancements, global access to new tools, particularly in low-resource settings, remains a challenge. However, to utilize these technologies in the full spectrum of future outbreak responses, investments in manufacturing capacity, cold chain logistics, and regulatory harmonization will be crucial (Kallel & Kamen, 2015).



Figure 1: *This flowchart illustrates the key stages in developing a vaccine for emerging infectious diseases, from pathogen detection to immunization, including fast-track options like EUA.*

5. CASE STUDIES OF SUCCESSFUL VACCINE DEVELOPMENT

Recent success stories in vaccine development shed light on the intersection of science, policy, and partnerships in tackling new infectious challenges. Recent history has seen some of the most pronounced examples of this, including the record-breaking development of COVID-19 vaccines. Therefore, multiple vaccines were authorized for emergency use approximately one year after the identification of SARS-CoV-2. The Pfizer-BioNTech and Moderna mRNA vaccines represent a historic turning point in immunization, demonstrating the rapid potential for next-generation platforms to be deployed at scale with safety and effectiveness (Selleck & Macreadie, 2022). In early trials, these vaccines showed 90% or greater efficacy against symptomatic infection, and they reduced hospitalization and mortality in several populations (Mao et al., 2023).

The second major success story was in the field of Ebola virus disease, specifically with the rVSV-ZEBOV vaccine. This recombinant vesicular stomatitis virus-

vectored vaccine showed high efficacy during the West African Ebola outbreak of 2014–2016, and its development involved international collaboration in research and production between the World Health Organization, the Public Health Agency of Canada, and the pharmaceutical industry (Yen et al., 2015). Although there were complications with the rollout of the vaccine, it ultimately helped mitigate subsequent outbreaks in the DRC. It also emphasizes the need for rapid regulatory pathways and emergency stockpiles for high-transmissibility, high-fatality pathogens that are expected to have sporadic spread patterns (Noad et al., 2019).

The relatively low efficacy achieved with the RTS, S/AS01 malaria vaccine heralds a paradigm shift in controlling a previously intractable, complex parasitic disease. It was endorsed by the WHO for pilot implementation in sub-Saharan Africa in 2021 and has been shown to reduce the incidence of severe malaria and childhood hospital admissions. This case highlights the need for such innovation even at lower levels of vaccine effectiveness; even a partially protective vaccine may confer important population-level benefits in high-burden regions (Asante et al., 2016).

The case studies highlight several consistent features associated with successful vaccine development, including early investment in research and development, global cooperation, flexible funding processes, and adaptable regulatory systems. They also highlighted the importance of transparent and community-engaged public outreach to achieve high uptake and trust (Weiser et al., 2018). These experiences are valuable not only for developing new vaccines but also for making the world more ready and resilient to respond to future pandemics. To continue delivering these successes in future emerging infectious diseases, ongoing investment in more innovative platforms, manufacturing capacity, and equitable access will be required (Gauld et al., 2020).

6. THE IMPACT OF VACCINATION ON PUBLIC HEALTH

Vaccination is one of the most cost-effective and widely practiced public health interventions. Its benefits are clear, not just for each disease, but also for reducing the population-level disease burden, mortality, and healthcare costs. Vaccines have eradicated or nearly eradicated several infectious diseases, including smallpox and poliomyelitis, and have significantly reduced the prevalence of measles, tetanus, diphtheria, and pertussis over the past century. Such outcomes have substantially increased life expectancy and minimized morbidity within the population, especially among children and other vulnerable portions of society (Rémy et al., 2015).

Vaccination plays a significant role in creating herd immunity. Vaccination also creates herd immunity, which occurs when contagious diseases cannot spread because enough of the population is immune to protect those who cannot yet be vaccinated due to medical reasons. Such indirect protection is essential for the most vulnerable members of society, such as newborns, people with weakened immune systems, and the elderly (Puggina et al., 2025). One remedy has been to achieve extensive vaccination, exemplified by the general decline in measles outbreaks worldwide (despite periodic lapses due to vaccine hesitancy). The extent of these mass immunizations around the world differed (in terms of effectiveness and coverage), and the COVID-19 vaccination campaigns also illustrated how the presence of mass immunization could reduce hospitalizations, severe cases, and ultimately the number of cases of infections as a whole (Bilgin et al., 2023).

In addition, the impact of vaccines on public health is also reflected in economic and systemic matters. Vaccines also alleviate the strain on health systems, liberate resources, and reduce treatment costs by preventing disease. With every dollar invested in immunization in low- and middle-income countries expected to generate an economic return of around $44, the World Health Organization estimates that continued investment in immunization saves at least 3 million lives every year (Peasah et al., 2019). By reducing missed work and school days and avoiding population movement restrictions, vaccination helps keep life as normal as possible during epidemics, allowing social and economic activities to continue. The indirect benefits became especially clear during the COVID-19 pandemic, when effective vaccination campaigns contributed to the stabilization of health systems and economies (Pecenka et al., 2021).

Nonetheless, these important interventions are not always fully available due to a range of impediments, including limited access, practical considerations, and

skepticism in the general population about their utility. The success of vaccination campaigns cannot solely depend on science; there needs to be investment in health infrastructure, education, and equitable implementation of policies (Rafferty et al., 2023). Whether vaccines will have a long-term public health impact ultimately hinges on how countries successfully tackle these challenges and how effectively future initiatives can build on lessons learned from previous and ongoing vaccination campaigns (Doherty et al., 2018).

7. GLOBAL VACCINE DISTRIBUTION AND EQUITY

Although vaccine development has enhanced the preparedness response to potential emerging infectious diseases, fair allocation continues to be a global issue. The COVID-19 pandemic has revealed extreme inequalities in access to vaccines between high- and low- or middle-income countries (LMICs). At this stage in mid-2022, most wealthier countries had achieved booster coverage, whereas many, if not most, LMICs had not been able to secure enough doses for at least primary immunization. Such inequities threaten health security and turn pandemics into protracted affairs that can last if the virus finds transmission opportunities and variants continue to emerge. There are several reasons why vaccines are not distributed equitably. A key problem is the unequal distribution of manufacturing capacity, with most vaccine production concentrated in a handful of countries (Mortiboy et al., 2024). Such centralization restricts availability to other users, particularly during times of high global demand. This breach is further exacerbated by intellectual property limitations, inadequate technology transfer, and insufficient storage and distribution infrastructure (e.g., cold chain logistics). Vaccines donated or purchased through global initiatives such as COVAX may become less effective upon arrival in recipient countries due to delays, a short shelf life, and inadequate logistics (Pushkaran et al., 2024).

Responses to these challenges have included international initiatives such as the COVID-19 Vaccines Global Access (COVAX) facility, spearheaded by Gavi, the WHO, and CEPI. COVAX did some great work and sent vaccines to areas of the world that needed them most. However, ultimately, its efforts were limited by supply shortages and its overall reliance on donations from wealthier countries (Nuhu et al., 2022). Sustainable solutions lie in regional capacity building, supporting local regulatory agencies, and investing in strengthening the health system. Efforts in Africa, India, and Southeast Asia to establish mRNA and other vaccine manufacturing plants are significant steps toward achieving self-reliance (Kunyenje et al., 2023).

However, equitable vaccine distribution must also be grounded in sociopolitical and economic solutions beyond the technical and logistical realms. Even if vaccines are available, public distrust, misinformation, and vaccine hesitancy can inhibit their uptake. Strategies for culturally sensitive communication and engagement with community leaders are crucial for rebuilding trust and acceptance. Finally, the policies regulating health globally need to be reflective of transparency, equitable access, and solidarity to ensure that no "vaccine nationalism" takes place and that vulnerable groups are not neglected (Sina-Odunsi, 2021).

To achieve substantial progress in vaccine equity, it is imperative to approach it not as a short-term, reactive endeavor but as one grounded in long-term planning through capacity building, resource sharing, and global cooperation. The promise of immunization as a protector of global public health will not be fulfilled unless all nations have equitable and timely access to vaccines (Ye et al., 2022).

8. FUTURE DIRECTIONS

Recent pandemics and the ever-changing landscape of global health threats will ultimately influence the future of vaccine development and deployment as shown in Figure 3. Emerging infectious diseases are targeting the world at an ever-increasing rate, and vaccine research must evolve towards broader-spectrum, scalable solutions that enable this. A key priority is the development of universal vaccines that incorporate conserved aspects of the pathogen, thereby reducing the need for frequent updates. Work is already underway to develop universal influenza and coronavirus vaccines that would protect against multiple variants or strains, thereby vastly enhancing global capacity (Pardi et al., 2018).

One area with great potential is the incorporation of elements of customized medicine and precision

immunology into vaccine design. Combining genetic, immunological, and microbiome data enables future vaccines to be personalized to the host population's immune response, thereby increasing their effectiveness and minimizing deleterious effects. This strategy is especially pertinent for groups likely to be more heterogeneously responsive to standard vaccines, such as the elderly and many immunocompromised individuals. In addition, artificial intelligence and machine learning are being employed to accelerate antigen discovery, predict immune responses, and optimize vaccine formulations to reduce development time without compromising safety and efficacy (Hudson et al., 2023).

At the structural level, global surveillance systems and response infrastructure must be overhauled. Real-time genomic sequencing data sharing and early warning systems require bolstering through international cooperation and sustained investment. Future vaccine cupboards require a decentralized capacity and regional hubs, wherever and whenever possible, to produce the required vaccines during health emergencies (Breiteneder et al., 2019). As such, having a harmonized regulatory framework to ensure that individual initiatives fall within the range of flexible yet expedited approval, so that countries can access these new mechanisms promptly, is equally important. Public-private partnerships, flexible fund models, and tech transfer agreements are key drivers of preparedness for future outbreaks (Vallin et al., 2024).

Most importantly, equity and trust in public health should remain at the center stage of global vaccine strategies. In addition to manufacturing and supplying vaccines, this involves investing in efforts to understand community concerns about vaccination, providing health education, and communicating clearly throughout the process (Larson et al., 2016). Trust in scientific and healthcare systems is essential for the acceptance of vaccines, particularly in regions where misinformation or historical grievances are prevalent, as these areas are likely to present the most significant challenges in persuading individuals to receive vaccinations. More than just rebuilding for the short term, our long-term objective needs to be a sustainable, adaptable, and equitable global health system that empowers nations of all income levels to manage the risk of future infectious disease outbreaks (Sheikhhossein et al., 2024).



Figure 3: *A resilient global vaccination strategy centers on vaccine preparedness, supported by six key pillars ensuring effectiveness and sustainability.*

9. CONCLUSION

Creating vaccines for emerging infectious diseases is a crucial element of global health security, offering the most effective strategy for preventing outbreaks, saving lives, and ensuring that health systems remain operational. The ongoing biological threats in the world today, ranging from new zoonotic viruses to antibiotic-resistant bacteria, have generated an urgent need for accelerated, scalable, and equitable vaccine development strategies. Technological advancements (mRNA platforms, viral vectors, and AI-based antigen discovery) have also shown great promise in shortening vaccine timelines and improving immunity. However, scientific innovation is insufficient. The ability of vaccines to effect real change continues to be muted, particularly in lower- and middle-income countries, due to ongoing issues with global distribution, public trust, regulatory

coordination, and infrastructure deficiencies. These inequalities were brought to the forefront with the onset of the COVID-19 pandemic, which inevitably led to evidence of poor or limited access, resulting in prolonged public health emergencies and hindered paths to recovery. Addressing these systemic failures will require future strategies focused on universal vaccine platforms, localized manufacturing capacity, and real-time surveillance, combined with coordinated international policies to guarantee fair and timely access. In addition, vaccination success extends beyond the technical efficacy of vaccines and requires ongoing investment in transparent and accountable communication, as well as community engagement. Vaccines can be a fundamental part of the pivot that the global health community needs to shift from reactive crisis management to proactive preparedness as new infectious threats continue to emerge. An enhanced focus on scientific cooperation, expanding innovation, and ensuring equitable access is required to lay the foundation for a strong global health system that can safeguard all communities from future outbreaks.

REFERENCES

Asante, K. P., Adjei, G., Enuameh, Y., & Owusu-Agyei, S. (2016). RTS, S malaria vaccine development: progress and considerations for postapproval introduction. *Vaccine: Development and Therapy*, 25-32.

Ayenigbara, I. O., Adegboro, J. S., Ayenigbara, G. O., Adeleke, O. R., & Olofintuyi, O. O. (2021). The challenges to a successful COVID-19 vaccination programme in Africa. *Germs*, *11*(3), 427.

Ben Hamouda, W., Hanachi, M., Ben Hamouda, S., Kammoun Rebai, W., Gharbi, A., Baccouche, A., Bettaieb, J., Souiai, O., Barbouche, M. R., & Dellagi, K. (2024). A Longitudinal Study in Tunisia to Assess the Anti-RBD IgG and IgA Responses Induced by Three Different COVID-19 Vaccine Platforms. *Tropical Medicine and Infectious Disease*, *9*(3), 61.

Bilgin, G. M., Munira, S. L., Lokuge, K., & Glass, K. (2023). Cost-effectiveness analysis of a maternal pneumococcal vaccine in low-income, high-burden settings such as Sierra Leone. *PLOS Global Public Health*, *3*(8), e0000915.

Boland, M., & O'Riordan, M. (2019). Preparedness and management of global public health threats at points of entry in Ireland and the EU in the context of a potential Brexit. *Globalization and Health*, *15*, 1-9.

Breiteneder, H., Diamant, Z., Eiwegger, T., Fokkens, W. J., Traidl-Hoffmann, C., Nadeau, K., O'Hehir, R. E., O'Mahony, L., Pfaar, O., & Torres, M. J. (2019). Future research trends in understanding the mechanisms underlying allergic diseases for improved patient care. *Allergy*, *74*(12), 2293-2311.

Czechowicz, S. (2021). Legal Guarantees for the Protection of Public Health Against the Spread of Infectious Diseases-New Challenges and Threats. *Medicine, Law & Society*, *14*(1), 77-94.

Doherty, T. M., Connolly, M. P., Del Giudice, G., Flamaing, J., Goronzy, J. J., Grubeck-Loebenstein, B., Lambert, P.-H., Maggi, S., McElhaney, J. E., & Nagai, H. (2018). Vaccination programs for older adults in an era of demographic change. *European geriatric medicine*, *9*, 289-300.

Gauld, N., Martin, S., Sinclair, O., Petousis-Harris, H., Dumble, F., & Grant, C. C. (2020). A qualitative study of views and experiences of women and health care professionals about free maternal vaccinations administered at community pharmacies. *Vaccines*, *8*(2), 152.

Gopinathan, U., Peacocke, E., Gouglas, D., Ottersen, T., & Røttingen, J.-A. (2020). R&D for emerging infectious diseases of epidemic potential: sharing risks and benefits through a new coalition. *Infectious Diseases in the New Millennium: Legal and Ethical Challenges*, 137-165.

Hudson, D., Fernandes, R. A., Basham, M., Ogg, G., & Koohy, H. (2023). Can we predict T cell specificity with digital biology and machine learning? *Nature Reviews Immunology*, *23*(8), 511-521.

Kallel, H., & Kamen, A. A. (2015). Large-scale adenovirus and poxvirus-vectored vaccine manufacturing to enable clinical trials. *Biotechnology Journal*, *10*(5), 741-747.

Konda, M., Dodda, B., Konala, V. M., Naramala, S., & Adapa, S. (2020). Potential zoonotic origins of SARS-CoV-2 and insights for preventing future pandemics through one health approach. *Cureus*, *12*(6).

Kunyenje, C. A., Chirwa, G. C., Mboma, S. M., Ng'ambi, W., Mnjowe, E., Nkhoma, D., Ngwira, L. G., Chawani, M. S., Chilima, B., & Mitambo, C. (2023). COVID-19 vaccine inequity in African low-income countries. *Frontiers in public health*, *11*, 1087662.

Larson, H. J., De Figueiredo, A., Xiahong, Z., Schulz, W. S., Verger, P., Johnston, I. G., Cook, A. R., & Jones, N. S. (2016). The state of vaccine confidence 2016: global insights through a 67-country survey. *EBioMedicine*, *12*, 295-301.

Liao, H., Lyon, C. J., Ying, B., & Hu, T. (2024). Climate change, its impact on emerging infectious diseases and new technologies to combat the challenge. *Emerging microbes & infections*, *13*(1), 2356143.

Lundstrom, K. (2020). Application of viral vectors for vaccine development with a special emphasis on COVID-19. *Viruses*, *12*(11), 1324.

Mahoney, R., Hotez, P. J., & Bottazzi, M. E. (2023). Global regulatory reforms to promote equitable vaccine access in the next pandemic. *PLOS Global Public Health*, *3*(10), e0002482.

Mao, W., Zimmerman, A., Hodges, E. U., Ortiz, E., Dods, G., Taylor, A., & Udayakumar, K. (2023). Comparing research and development, launch, and scale up timelines of 18 vaccines: lessons learnt from COVID-19 and implications for other infectious diseases. *BMJ Global Health*, *8*(9), e012855.

Maslow, J. N. (2019). Challenges and solutions in the development of vaccines against emerging and neglected infectious diseases. *Human Vaccines & Immunotherapeutics*, *15*(10), 2230-2234.

Mortiboy, M., Zitta, J.-P., Carrico, S., Stevens, E., Smith, A., Morris, C., Jenkins, R., & Jenks, J. D. (2024). Combating COVID-19 vaccine inequity during the early stages of the COVID-19 pandemic. *Journal of racial and ethnic health disparities*, *11*(2), 621-630.

Mostafavi, E., Ghasemian, A., Abdinasir, A., Mahani, S. A. N., Rawaf, S., Vaziri, M. S., Gouya, M. M., Nguyen, T. M. N., Al Awaidy, S., & Al Ariqi, L. (2021). Emerging and re-emerging infectious diseases in the WHO Eastern Mediterranean region, 2001-2018. *International journal of health policy and management*, *11*(8), 1286.

Nii-Trebi, N. I. (2017). Emerging and neglected infectious diseases: insights, advances, and challenges. *BioMed Research International*, *2017*(1), 5245021.

Noad, R. J., Simpson, K., Fooks, A. R., Hewson, R., Gilbert, S. C., Stevens, M. P., Hosie, M. J., Prior, J., Kinsey, A. M., & Entrican, G. (2019). UK vaccines network: Mapping priority pathogens of epidemic potential and vaccine pipeline developments. *Vaccine*, *37*(43), 6241-6247.

Nuhu, K., Humagain, K., Alorbi, G., Thomas, S., Blavos, A., & Placide, V. (2022). Global COVID-19 case fatality rates influenced by inequalities in human development and vaccination rates. *Discover Social Science and Health*, *2*(1), 20.

Ogden, N., AbdelMalik, P., & Pulliam, J. (2017). Emerging infectious diseases: prediction and detection. *Canada Communicable Disease Report*, *43*(10), 206.

Pardi, N., Hogan, M. J., Porter, F. W., & Weissman, D. (2018). mRNA vaccines—a new era in vaccinology. *Nature reviews Drug discovery*, *17*(4), 261-279.

Peasah, S. K., Meltzer, M. I., Vu, M., Moulia, D. L., & Bridges, C. B. (2019). Cost-effectiveness of increased influenza vaccination uptake against readmissions of major adverse cardiac events in the US. *PloS one*, *14*(4), e0213499.

Pecenka, C., Usuf, E., Hossain, I., Sambou, S., Vodicka, E., Atherly, D., & Mackenzie, G. (2021). Pneumococcal conjugate vaccination in The Gambia: health impact, cost effectiveness and budget implications. *BMJ Global Health*, *6*(12), e007211.

Pinschewer, D. D. (2017). Virally vectored vaccine delivery: medical needs, mechanisms, advantages and challenges. *Swiss medical weekly*, *147*(3132), w14465-w14465.

Puggina, A., Rumi, F., Zarkadoulas, E., Marijam, A., & Calabró, G. E. (2025). The Potential Public Health Impact of the Adjuvanted Respiratory Syncytial Virus Prefusion F Protein Vaccine Among Older Adults in Italy. *Vaccines*, *13*(3), 212.

Pushkaran, A., Chattu, V. K., & Narayanan, P. (2024). COVAX and COVID-19 Vaccine Inequity: A case study of G-20 and African Union. *Public Health Challenges*, *3*(2), e185.

Rafferty, E., Unsal, A., Kirwin, E., of Alberta, U., of Manchester, U., & Kingdom, U. (2023). Healthcare costs and effects of post-COVID-19 condition in Canada. *Canada Communicable Disease Report*, *49*(10), 425.

Rémy, V., Zöllner, Y., & Heckmann, U. (2015). Vaccination: the cornerstone of an efficient healthcare system. *Journal of market access & health policy*, *3*(1), 27041.

Reperant, L. A., MacKenzie, J., & Osterhaus, A. D. (2016). Periodic global One Health threats update. *One Health*, *2*, 1-7.

Roberts, C. C. (2019). Emerging infectious disease laboratory and diagnostic preparedness to accelerate vaccine development. *Human Vaccines & Immunotherapeutics*, *15*(10), 2258-2263.

Rose, N. J., Stickings, P., Schepelmann, S., Bailey, M. J., & Burns, C. (2021). National control laboratory independent lot testing of COVID-19 vaccines: the UK experience. *npj Vaccines*, *6*(1), 100.

Sa, S., Lee, C. W., Shim, S. R., Yoo, H., Choi, J., Kim, J. H., Lee, K., Hong, M., & Han, H. W. (2022). The safety of mRNA-1273, BNT162b2 and JNJ-78436735 COVID-19 vaccines: safety monitoring for adverse events using real-world data. *Vaccines*, *10*(2), 320.

Sandbrink, J. B., & Koblentz, G. D. (2022). Biosecurity risks associated with vaccine platform technologies. *Vaccine*, *40*(17), 2514-2523.

Selleck, P., & Macreadie, I. (2022). Vaccine technologies used to develop COVID-19 vaccines. *Microbiology Australia*, *43*(1), 40-43.

Sheikhhossein, H. H., Iommelli, F., Di Pietro, N., Curia, M. C., Piattelli, A., Palumbo, R., Roviello, G. N., & De Rosa, V. (2024). Exosome-like systems: from therapies to vaccination for cancer treatment and prevention—Exploring the state of the art. *Vaccines*, *12*(5), 519.

Shoaib, N., Qureshi, M. A., & Latif, M. Z. (2023). Covid-19 Vaccine Hesitancy: Frequency and causes among Population of Lahore. *Pakistan Journal of Medical & Health Sciences*, *17*(02), 139-139.

Silva-Jr, F. P., Panda, S. S., Andrade, C. H., & Furnham, N. (2022). Current approaches in infectious disease drug discovery. *Frontiers in Chemistry*, *10*, 1102402.

Sina-Odunsi, A. J. (2021). COVID-19 vaccines inequity and hesitancy among African Americans. *Clinical Epidemiology and Global Health*, *12*, 100876.

Steinman, A., & Navon-Venezia, S. (2020). Antimicrobial resistance in horses. In (Vol. 10, pp. 1161): MDPI.

Tao, C. C., Lim, X.-J., Amer Nordin, A., Thum, C. C., Sararaks, S., Periasamy, K., & Rajan, P. (2022). Health system preparedness in infectious diseases: perspective of Malaysia, a middle-income country, in the face of monkeypox outbreaks. *Tropical medicine and health*, *50*(1), 87.

Travieso, T., Li, J., Mahesh, S., Mello, J. D. F. R. E., & Blasi, M. (2022). The use of viral vectors in vaccine development. *npj Vaccines*, *7*(1), 75.

Vallin, M., Tomson, G., Kampmann, B., Engebretsen, E., Swartling Peterson, S., Wanyenze, R. K., & Ottersen, O. P. (2024). Life Science 2.0: reframing the life science sector for 'the benefit on mankind'. *Global Health Action*, *17*(1), 2330758.

van den Ouweland, F., Charpentier, N., Türeci, Ö., Rizzi, R., Mensa, F. J., Lindemann, C., & Pather, S. (2024). Safety and reactogenicity of the BNT162b2 COVID-19 vaccine: Development, post-marketing surveillance, and real-world data. *Human Vaccines & Immunotherapeutics*, *20*(1), 2315659.

Weiser, J., Perez, A., Bradley, H., King, H., & Shouse, R. L. (2018). Low prevalence of hepatitis B vaccination among patients receiving medical care for HIV infection in the United States, 2009 to 2012. *Annals of internal medicine*, *168*(4), 245-254.

Wolf, J., Bruno, S., Eichberg, M., Jannat, R., Rudo, S., VanRheenen, S., & Coller, B.-A. (2020). Applying lessons from the Ebola vaccine experience for SARS-CoV-2 and other epidemic pathogens. *npj Vaccines*, *5*(1), 51.

Yan, C., Zhou, Y., Du, S., Du, B., Zhao, H., Feng, Y., Xue, G., Cui, J., Gan, L., & Feng, J. (2023). Recombinase-aided amplification assay for rapid detection of hypervirulent Klebsiella pneumoniae (hvKp) and characterization of the hvKp pathotype. *Microbiology Spectrum*, *11*(2), e03984-03922.

Ye, Y., Zhang, Q., Wei, X., Cao, Z., Yuan, H.-Y., & Zeng, D. D. (2022). Equitable access to COVID-19 vaccines makes a life-saving difference to all countries. *Nature human behaviour*, *6*(2), 207-216.

Yen, C., Hyde, T. B., Costa, A. J., Fernandez, K., Tam, J. S., Hugonnet, S., Huvos, A. M., Duclos, P., Dietz, V. J., & Burkholder, B. T. (2015). The development of global vaccine stockpiles. *The Lancet Infectious Diseases*, *15*(3), 340-347.

Zegpi, R., Breedlove, C., van Santen, V., Rasmussen-Ivey, C., & Toro, H. (2017). Kidney cell–adapted infectious bronchitis ArkDPI vaccine is stable and protective. *Avian Diseases*, *61*(2), 221-228.